Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Salivary Hormone Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentMutual of OmahaPolicy AHS-G2120

    Salivary Hormone Testing

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-G2120 alerts

    Get alerted when Policy AHS-G2120 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of salivary testing for steroid hormones, including cortisol, estrogen, progesterone, and androgens. It distinguishes covered late-night salivary cortisol testing for individuals with signs and symptoms of Cushing syndrome from excluded screening, diagnostic, and monitoring uses.

    Policy Summary
    PayerMutual of Omaha
    PolicySalivary Hormone Testing
    Policy CodePolicy N/A
    Change TypeLiterature and reference updateno material coverage change
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument signs and symptoms of Cushing syndrome when requesting covered late-night salivary cortisol testing.
    SourceLink
    POLICY UPDATE CHANGES

    The 03/18/2026 revision updated the background, guidelines and recommendations, and evidence-based scientific references.

    1Covered clinical indication
    12Excluded indications
    At least 2Measurements for Cushing syndrome evaluation
    4Procedure codes listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Cushing Syndrome Evaluation

    Late night salivary cortisol testing is covered when the individual has signs and symptoms of Cushing syndrome.

    The individual has signs and symptoms of Cushing syndrome and is being evaluated with late night salivary cortisol testing.

    Excluded Screening, Diagnostic, and Monitoring Uses

    Salivary hormone testing does not meet coverage criteria for the following uses because published scientific literature confirming that the testing is required and beneficial for diagnosis or treatment is lacking.

    ONE or more of the following uses:

    • Screening, diagnosis, or monitoring of menopause.
    • Screening, diagnosis, or monitoring of infertility.
    • Screening, diagnosis, or monitoring of endometriosis.
    • Screening, diagnosis, or monitoring of polycystic ovary disease (PCOS).
    • Screening, diagnosis, or monitoring of premenstrual syndrome.
    • Screening, diagnosis, or monitoring of osteoporosis.
    • Screening, diagnosis, or monitoring of sexual dysfunction.
    • Screening, diagnosis, or monitoring of seasonal affective disorder.
    • Screening, diagnosis, or monitoring of depression.
    • Screening, diagnosis, or monitoring of multiple sclerosis.
    • Screening, diagnosis, or monitoring of sleep disorders.
    • Screening, diagnosis, or monitoring of diseases related to aging.

    Salivary hormone testing for menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome, osteoporosis, or sexual dysfunction does not meet coverage criteria. There is insufficient published scientific literature confirming that the testing is required and beneficial for diagnosis or treatment of an individual's illness.

    Salivary sex-hormone testing used to individualize hormone therapy or to correct sex-hormone levels does not meet coverage criteria. The American Association of Clinical Endocrinologists has noted that these methods are not FDA- or CLIA-approved; hydration and circadian rhythm can affect hormone concentrations, standardization is difficult, and salivary measurements cannot be used to correct sex-hormone levels. Measuring hormone levels in postmenopausal individuals also has no predictive value for determining what normal levels should be.

    Salivary hormone testing does not provide an accurate or precise assessment of hormone levels for individualized hormone therapy. ACOG and ASRM guidance reports large intra-patient variability, effects from diet, poor representation of serum hormone levels, possible contamination with other cell types, and lower hormone concentrations than serum. Evidence is inadequate to support individualized hormone therapy based on salivary, serum, or urine testing. There is no evidence that hormone levels in saliva are biologically meaningful; estrogen levels are extremely low and difficult to measure, progesterone levels in saliva may not reflect tissue levels, and there are currently no FDA-approved salivary or urinary tests for steroid hormone measurement.

    Covered Clinical Indications

    Signs and Symptoms of Cushing Syndrome

    Late-night salivary cortisol testing meets coverage criteria when the individual has signs and symptoms of Cushing syndrome.

    Covered indication: The individual has signs and symptoms of Cushing syndrome.

    Diagnosis of Cushing Syndrome Using Late-Night Salivary Cortisol

    For diagnostic evaluation of Cushing syndrome, the Endocrine Society recommends obtaining at least two late-night salivary cortisol measurements.

    Diagnostic evaluation

    • The testing is being used for diagnosis of Cushing syndrome.
    • At least two late-night salivary cortisol measurements are obtained.At least 2 measurements

    Testing Frequency and Abnormal Results

    Late-night salivary cortisol
    Measurements obtainedAt least two late-night salivary cortisol measurements are obtained; two measurements must be abnormal for the test to be considered abnormal.
    Late-night salivary cortisol
    Recommended measurementsAt least 2 late-night salivary cortisol measurements are recommended for the diagnostic evaluation of Cushing syndrome.

    Coding and Clinical Thresholds

    Applicable CPT/HCPCS Procedure CodesCPT
    82530Cortisol; free
    82533Cortisol; total
    S3650Saliva test, hormone level; during menopause
    0462UMelatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary Proprietary Test: Salimetrics® Salivary Melatonin Profile (Circadian Phase Assessment) Lab/Manufacturer: Salimetrics® Clinical Laboratory, Salimetrics®, LLC
    Pediatric bedtime salivary cortisol screening
    Pediatric bedtime thresholdGreater than 2.4 nmol/L.
    Post-cosyntropin salivary cortisol
    Post-cosyntropin thresholdGreater than or equal to 12.6 nmol/L at 60 minutes; this level was optimal for ruling out adrenal insufficiency.
    Cushing syndrome diagnosis
    Diagnostic measurementsAt least 2 late-night salivary cortisol measurements.

    Documentation and Denial Risks

    Documentation Required

    Document Cushing Syndrome Signs and Symptoms

    When requesting covered late-night salivary cortisol testing, document that the individual has signs and symptoms of Cushing syndrome.

    Denial Risk

    Excluded Salivary Hormone Testing Indications

    Salivary hormone testing does not meet coverage criteria for screening, diagnosis, or monitoring of the conditions listed below because published scientific evidence does not establish that testing is required and beneficial for diagnosis or treatment.

    • Menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome, and osteoporosis
    • Sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, and diseases related to aging
    Denial Risk

    Do Not Use Salivary Testing to Individualize Hormone Therapy

    Do not use salivary hormone results to individualize or monitor hormone therapy. ACOG and ASRM guidance states that salivary testing does not provide an accurate or precise assessment of hormone levels and is not sufficiently reliable to guide individualized therapy.

    • Salivary hormone levels have substantial intra-patient variability and may be affected by diet, contamination with other cell types, and lower hormone concentrations than serum.
    • Saliva does not provide a reasonable or reliable representation of serum or tissue hormone levels; evidence is inadequate to support individualized hormone therapy based on salivary, serum, or urine testing.
    • There are no FDA-approved salivary or urinary tests for steroid hormone measurement. The ACOG/ASRM guidance was reaffirmed in 2023.

    Background

    Salivary hormone testing has been proposed as a noninvasive method for measuring free, or unbound, steroid hormones and for guiding individualized hormone replacement therapy. Although saliva theoretically may reflect free hormone concentrations, current testing does not provide an accurate or precise assessment for this purpose.

    Definitions and Abbreviations

    Definitions
    AACEAmerican Association of Clinical Endocrinologists.
    Definitions
    ACOGAmerican College of Obstetricians and Gynecologists.
    Definitions
    ACTHAdrenocorticotropic hormone.
    Definitions
    AIAdrenal insufficiency.
    Definitions
    ASRMAmerican Society of Reproductive Medicine Practice Committee.
    Definitions
    CLIA '88Clinical Laboratory Improvement Amendments of 1988.
    Definitions
    CMSCenters for Medicare and Medicaid Services.
    Definitions
    CSCushing syndrome.
    Definitions
    DHEADehydroepiandrosterone.
    Definitions
    E1Estrone.
    Definitions
    E2Estradiol.
    Definitions
    E3Estriol.
    Definitions
    EIAEnzyme immunoassay.
    Definitions
    ELISAEnzyme-linked immunosorbent assay.
    Definitions
    ERCUSYNEuropean Registry on Cushing's Syndrome.
    Definitions
    ESEndocrine Society.
    Definitions
    FDAFood and Drug Administration.
    Definitions
    HTHormone therapy.
    Definitions
    IVFIn vitro fertilization.
    Definitions
    LC-MSLiquid chromatography with tandem mass spectrometry.
    Definitions
    LDTsLaboratory-developed tests.
    Definitions
    LNSCLate-night salivary cortisol.
    Definitions
    MHTMenopausal hormone therapy.
    Definitions
    MPMicronized progesterone.
    Definitions
    MSMultiple sclerosis.
    Definitions
    NAMSNorth American Menopausal Society.
    Definitions
    PCOSPolycystic ovary disease.
    Definitions
    RIARadioimmunoassay.
    Definitions
    TSSTranssphenoidal selective adenomectomy.
    Laboratory-developed tests
    Laboratory-developed test (LDT)A laboratory-specific test developed and validated for in-house performance. LDTs are regulated by CMS as high-complexity tests under CLIA, and FDA clearance or approval is not currently required for clinical use.
    Laboratory regulation
    CLIAThe Clinical Laboratory Improvement Amendments of 1988; LDTs are regulated as high-complexity tests under CLIA.

    Not Covered Services

    The following uses are not covered: salivary hormone testing for screening, diagnosis, or monitoring of menopause, infertility, endometriosis, polycystic ovary disease, premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or diseases related to aging. Salivary sex-hormone testing used to guide individualized hormone replacement therapy or correct sex-hormone levels is also unsupported and not covered.

    Policy Summary
    PayerMutual of Omaha
    PolicySalivary Hormone Testing
    Policy CodePolicy N/A
    Change TypeLiterature and reference updateno material coverage change
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDocument signs and symptoms of Cushing syndrome when requesting covered late-night salivary cortisol testing.
    SourceLink
    On This Page
    Coverage CriteriaCovered Clinical IndicationsTesting Frequency and Abnormal ResultsCoding and Clinical ThresholdsDocumentation and Denial RisksBackgroundDefinitions and AbbreviationsNot Covered Services